BIOEMTECH is a fast-growing Greek SME in the field of biomedical engineering, bridging the gap between ex vivo studies and in vivo molecular imaging by providing solutions in terms of instrumentation, preclinical imaging and software services. The company designs and develops benchtop molecular imaging systems and provides imaging services and consultancy with emphasis in nuclear medicine technology. BIOEMTECH provides additional expertise on software medical solutions in terms of a) executing Monte Carlo simulations at multiscale level, b) developing Machine Learning algorithms and c) creating realistic computational models based on clinical and preclinical data. BIOEMTECH laboratories, provide preclinical services that cover a wide range of studies, from an in vitro level, to radiochemistry, animal hosting and multi-modal in vivo imaging, both with BIOEMTECH’s dynamic imaging systems and with high resolution tomographic systems for SPECT, PET, CT and optical in vivo imaging. BIOEMTECH provides great expertise in terms of Monte Carlo simulations, in a variety of applications, namely Medical Imaging, Dosimetry, Realistic Computational Models, Radiobiology.

BIOEMTECH is a multidisciplinary team of 18 young scientists with strong background in biomedical engineering, medical physics, bioinformatics, radiochemistry, biology and nanomedicine. The company was founded in 2013 and till now participated in 9 H2020, 4 ERANETs and 2 NSRF (National) research projects. BIOEMTECH developed 2 commercial benchtop imaging products “γ-eye” & “β-eye”, organizes educational/training and dissemination activities and is an official member of the OpenGATE, EARA and ETPN networks. In 2019 a pre-seed investment was obtained by the METAVALLON Venture Capital scheme. BIOEMTECH highlighted for excellence innovation for the ERROR project by the EC’s Innovation Radar platform and gained the H2020 Seal of Excellence in 2020.